Olaparib Tablets and Zyvox (Linezolid Suspension)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using olaparib together with linezolid may increase the risk of bone marrow impairment, which may lead to serious conditions known as Myelodysplastic Syndrome or Acute Myeloid Leukemia. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know if you experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib. The majority of cases were fatal, and the duration of therapy with olaparib in patients who developed secondary MDS/cancer-therapy related AML varied from less than 6 months to greater than 2 years. All patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents.

MANAGEMENT: Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy. For prolonged hematologic toxicities, olaparib should be interrupted and blood counts monitored weekly until recovery. If the levels have not recovered to CTCAE Grade 1 or less after 4 weeks, a haematologist should be consulted for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue olaparib. Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool.

Olaparib Tablets

Generic Name: olaparib

Brand name: Lynparza

Synonyms: Olaparib

What is Olaparib Tablets?

Zyvox (Linezolid Suspension)

Generic Name: linezolid

Brand name: Zyvox

Synonyms: Zyvox

What is Zyvox (Linezolid Suspension)?